What question did this study set out to answer?

This study evaluates the efficacy and safety of toripalimab with GEMOX for advanced biliary tract cancer as a first-line treatment.

February 2, 2026Open Access

Preliminary Application of Toripalimab in Combination With GEMOX Regimen as a First-Line Treatment Option for Advanced Biliary Tract Tumors

Key Points

This study evaluates the efficacy and safety of toripalimab with GEMOX for advanced biliary tract cancer as a first-line treatment.
Prospective, single-arm, single-center design
Enrollment of 35 patients with advanced biliary tract cancer
Patients received toripalimab in combination with GEMOX for up to 11 cycles
Objective response rate determined using RECIST criteria
Kaplan-Meier method for progression-free and overall survival assessment
Objective response rate was 20% with 2 complete responses and 5 partial responses
Median progression-free survival was 8.5 months
Median overall survival was 16.5 months
All patients experienced adverse events, with 31.42% having grade 3 or higher events
Common adverse events included elevated ALT, AST, leukopenia, neutropenia, and thrombocytopenia

Abstract

Aims/Background: Advanced biliary tract cancer (BTC) is an aggressive malignancy, and often presents with poor prognostic outcomes despite standard chemotherapy. This study aimed to evaluate the preliminary efficacy and safety of toripalimab in combination with gemcitabine + oxaliplatin (GEMOX) as a first-line treatment option for advanced BTC. Methods: This prospective, single-arm, single-center study enrolled 35 patients with advanced BTC. The patients received toripalimab in combination with GEMOX as first-line treatment at Zhejiang Cancer Hospital, China, between February 2021 and April 2023. Each patient received 1 to 11 treatment cycles, and the objective response rate (ORR) was evaluated before and after chemotherapy using the Response Evaluation Criteria for Solid Tumors (RECIST) version 1.1. Progression-free survival (PFS) and overall survival (OS) were assessed using the Kaplan-Meier method. Furthermore, adverse events and their severity were recorded to evaluate the safety profile of the treatment. Results: A study cohort of 35 patients was enrolled (median age, 57 years), including 15 men and 20 women. Of them, 18 had intrahepatic cholangiocarcinoma, 14 had gallbladder cancer, and 3 had hilar cholangiocarcinoma. Metastatic lesions were most commonly observed in the lymph nodes, liver, and pelvis. The ORR was 20% (95% confidence interval CI 8.4%–36.9%), including 2 for complete response (CR) and 5 for partial response (PR). The median PFS and OS were found to be 8.5 and 16.5 months, respectively. All patients experienced adverse events, with 11 (31.42%) of the patients having grade 3 or higher adverse events. The most commonly observed adverse events included increases in alanine aminotransferase (ALT) and aspartate aminotransferase (AST), leukopenia, neutropenia, and thrombocytopenia. Conclusion: Toripalimab combined with GEMOX showed preliminary antitumor activity and an acceptable safety profile in patients with advanced BTC, warranting further validation in larger cohorts. Clinical Trial Registration: Chinese Clinical Trial Registry (ChiCTR2600117154).

Preliminary Application of Toripalimab in Combination With GEMOX Regimen as a First-Line Treatment Option for Advanced Biliary Tract Tumors

Key Points

Abstract

Cite This Study

Also Consider

Also Consider